Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Rapid Characterization of the Major Drug-Metabolizing Human Hepatic Cytochrome P-450 Enzymes Expressed in Escherichia coli

Dermot F. McGinnity, Sarah J. Griffin, Graeme C. Moody, Mike Voice, Stephen Hanlon, Thomas Friedberg and Robert J. Riley
Drug Metabolism and Disposition September 1999, 27 (9) 1017-1023;
Dermot F. McGinnity
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah J. Griffin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Graeme C. Moody
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mike Voice
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen Hanlon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Friedberg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert J. Riley
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The major drug-metabolizing human hepatic cytochrome P-450s (CYPs; CYP1A2, 2C9, 2C19, 2D6, and 3A4) coexpressed functionally inEscherichia coli with human NADPH-P-450 reductase have been validated as surrogates to their counterparts in human liver microsomes (HLM) using automated technology. The dealkylation of ethoxyresorufin, dextromethorphan, and erythromycin were all shown to be specific reactions for CYP1A2, CYP2D6, and CYP3A4 that allowed direct comparison with kinetic data for HLM. For CYP2C9 and CYP2C19, the kinetics for the discrete oxidations of naproxen and diazepam were compared to data obtained using established, commercial CYP preparations. Turnover numbers of CYPs expressed in E. coli toward these substrates were generally equal to or even greater than those of the major commercial suppliers [CYP1A2 (ethoxyresorufin), E. coli 0.6 ± 0.2 min−1 versus B lymphoblasts 0.4 ± 0.1 min−1; CYP2C9 (naproxen), 6.7 ± 0.9 versus 4.9 min−1; CYP2C19 (diazepam), 3.7 ± 0.3 versus 0.2 ± 0.1 min−1; CYP2D6 (dextromethorphan), 4.7 ± 0.1 versus 4.4 ± 0.1 min−1; CYP3A4 (erythromycin), 3 ± 1.2 versus 1.6 min−1]. The apparentKm values for the specific reactions were also similar (Km ranges for expressed CYPs and HLM were: ethoxyresorufin 0.5–1.0 μM, dextromethorphan 1.3–5.9 μM, and erythromycin 18–57 μM), indicating little if any effect ofN-terminal modification on the E. coli-expressed CYPs. The data generated for all the probe substrates by HLM and recombinant CYPs also agreed well with literature values. In summary, E. coli-expressed CYPs appear faithful surrogates for the native (HLM) enzyme, and these data suggest that such recombinant enzymes may be suitable for predictive human metabolism studies.

Footnotes

  • Send reprint requests to: Dr. Robert Riley, Department of Physical & Metabolic Sciences, AstraZeneca R&D Charnwood, Bakewell Road, Loughborough, Leicestershire. LE11 5RH UK. E-mail:Rob.Riley{at}charnwood.gb.astra.com

  • We acknowledge support for this project from the Biotechnology & Biological Research Council, UK-Department of Trade and Industry, and the LINK consortium of pharmaceutical companies: Astra, Glaxo-Wellcome, Janssen Pharmaceutica, Lilly, Novo Nordisk, Parke-Davis, Pfizer, Roche Products, Sanofi-Winthrop, Servier, Smith-Kline Beecham, Wyeth-Ayerst, and Zeneca.

  • Abbreviations used are::
    CYP
    cytochrome P-450
    TN
    turnover number
    HLM
    human liver microsome(s)
    Clint
    intrinsic clearance
    EROD
    ethoxyresorufinO-deethylation
    β-NADPH
    β-nicotinamide adenine dinucleotide phosphate, reduced form
    RSP
    robotic sample processor
    SPE
    solid phase extraction
    • Received March 17, 1999.
    • Accepted June 15, 1999.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 27 (9)
Drug Metabolism and Disposition
Vol. 27, Issue 9
1 Sep 1999
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Rapid Characterization of the Major Drug-Metabolizing Human Hepatic Cytochrome P-450 Enzymes Expressed in Escherichia coli
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Rapid Characterization of the Major Drug-Metabolizing Human Hepatic Cytochrome P-450 Enzymes Expressed in Escherichia coli

Dermot F. McGinnity, Sarah J. Griffin, Graeme C. Moody, Mike Voice, Stephen Hanlon, Thomas Friedberg and Robert J. Riley
Drug Metabolism and Disposition September 1, 1999, 27 (9) 1017-1023;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Rapid Characterization of the Major Drug-Metabolizing Human Hepatic Cytochrome P-450 Enzymes Expressed in Escherichia coli

Dermot F. McGinnity, Sarah J. Griffin, Graeme C. Moody, Mike Voice, Stephen Hanlon, Thomas Friedberg and Robert J. Riley
Drug Metabolism and Disposition September 1, 1999, 27 (9) 1017-1023;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Sex- and lifestyle-related factors affect hepatic CYP levels
  • Adipocyte PXR does not play an essential role in obesity.
  • CYP3A-mediated oxidation of DABE and BIBR0951
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics